GlassScriptPhysician profile
Jefferson L Boulet
NPI 1740274745
$1,199.19
in general payments reported to CMS, 2019-2025
18 companies · $707 in 2025
The $707 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.59 · 2022: $31.96 · 2023: $86.68 · 2024: $336 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $490.80 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $184.71 | 2025 | Rexulti |
| Astellas Pharma US INC | $107.81 | 2023-2025 | Veozah |
| Lilly USA, LLC | $62.98 | 2024-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $38.76 | 2024-2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $34.28 | 2025 | Voquezna |
| Antares Pharma, INC. | $32.33 | 2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $31.17 | 2025 | |
| Glaxosmithkline, LLC. | $29.24 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $26.43 | 2025 | Gemtesa |
| Lundbeck LLC | $24.31 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $23.24 | 2025 | Austedo Xr |
| Viatris Specialty LLC | $22.03 | 2025 | Yupelri |
| Novo Nordisk INC | $21.19 | 2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $20.81 | 2025 | Farxiga |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.52 | 2025 | Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.09 | 2023 | Jardiance |
| Abbott Laboratories | $14.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jefferson Boulet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.